SynthesisThe Journal of international medical research2019
Efficacy and safety of tofacitinib for the treatment of chronic plaque psoriasis: a systematic review and meta-analysis.
Synthesis in The Journal of international medical research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Pooled it
- Coexistence of Multiple Cutaneous Leiomyomas and Psoriasis Vulgaris: A Case Report and Review of Pathogenetic Insights.Clinical, cosmetic and investigational dermatology · 2026Article
- Co-occurrence of endometriosis with psoriasis and psoriatic arthritis: Genetic insights (Review).Experimental and therapeutic medicine · 2025Review
- Exosomes as natural vectors for therapeutic delivery of bioactive compounds in skin diseases.Frontiers in pharmacology · 2025Review
- Contemplating Novel W/O Emulsion Based Gel for Anti-Psoriatic Activity of Tofacitinib in Imiquimod-Induced Balb/C Mice Model.AAPS PharmSciTech · 2024Article
- New and Emerging Oral/Topical Small-Molecule Treatments for Psoriasis.Pharmaceutics · 2024Review
- New and emerging oral therapies for psoriasis.Drugs in context · 2024Review
- A Transcriptome-Wide Analysis of Psoriasis: Identifying the Potential Causal Genes and Drug Candidates.International journal of molecular sciences · 2023Article
- Pharmaco-Omics in Psoriasis: Paving the Way towards Personalized Medicine.International journal of molecular sciences · 2023Review
- The genetic backbone of ankylosing spondylitis: how knowledge of genetic susceptibility informs our understanding and management of disease.Rheumatology international · 2022Review
- Various Application of Tofacitinib and Ruxolitinib (Janus Kinase Inhibitors) in Dermatology and Rheumatology: A Review of Current Evidence and Future Perspective.Dermatology practical & conceptual · 2022Review
- Efficacy and safety of JAK inhibitors in the treatment of psoriasis and psoriatic arthritis: a systematic review and meta-analysis.BMC rheumatology · 2022Article
- Halogenated Pyrrolopyrimidines with Low MIC onAntibiotics (Basel, Switzerland) · 2022Article
- Novel Therapeutic Approaches to Psoriasis and Risk of Infectious Disease.Biomedicines · 2022Review
- Review on Novel Oral Therapies for Psoriasis.The Journal of clinical and aesthetic dermatology · 2021Review
- Pharmacogenomics: An Update on Biologics and Small-Molecule Drugs in the Treatment of Psoriasis.Genes · 2021Review
- Integration ofFrontiers in immunology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTofacitinib is an oral Janus kinase (JAK) inhibitor that targets JAK1 and JAK3, and thus regulates immune response. Therefore, tofacitinib is used to treat immune-mediated inflammatory diseases such as chronic plaque psoriasis. The objective of this study was to systematically assess the efficacy and safety of tofacitinib in treating chronic plaque psoriasis.
objectiveTo systematically review the efficacy and safety of tofacitinib in the treatment of chronic plaque psoriasis, we performed a meta-analysis to evaluate the efficacy and safety of tofacitinib in patients with chronic plaque psoriasis.
methodsDatabases including PubMed, Embase, and The Cochrane Library were searched for randomized controlled trials about the efficacy and safety of tofacitinib in treating chronic plaque psoriasis from inception to August 2017 (PROSPERO Code No: CRD42017076587).
resultsSix articles (seven randomized controlled trial studies) involving 3743 patients were included. The meta-analysis results showed that for efficacy, tofacitinib (5 mg or 10 mg) compared with placebo can significantly improve the Physician's Global Assessment response, PASI75, and PASI90 after treatment. For safety, the incidence of adverse reactions was statistically significantly higher for tofacitinib compared with placebo.
conclusionTreatment of chronic plaque psoriasis with tofacitinib is effective, but there may be more adverse reactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.